Jaguar Health, Inc.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 20, 2026
JAGX$0.44+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| (in thousands) · 2026 · 2025 | ||||
| Cash flows from operating activities | ||||
| Net comprehensive income (loss) | $ | 8,265 | $ | (10,858) |
| Adjustments to reconcile net comprehensive loss to net cash used in operating activities: | ||||
| Loss on extinguishment of debt | 628 | — | ||
| Depreciation and amortization expenses | 473 | 479 | ||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | 337 | 1,343 | ||
| Interest accrued | 257 | — | ||
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 155 | 301 | ||
| Amortization of operating lease - right-of-use asset | 47 | 67 | ||
| Share in joint venture's loss | 9 | 33 | ||
| Changes in assets and liabilities | ||||
| Accounts receivable | 1,453 | 304 | ||
| Other receivable | (37) | (45) | ||
| Inventory | 780 | (209) | ||
| Prepaid expenses and other current assets | 231 | (487) | ||
| Other assets | 37 | — | ||
| Accounts payable | (3,755) | 1,723 | ||
| Accrued liabilities | 41 | 141 | ||
| Deferred revenue | (42) | (43) | ||
| Operating lease liability | (49) | (63) | ||
| Total cash provided by (used in) operating activities | 8,830 | (7,314) | ||
| Cash flows from financing activities | ||||
| Payment of 2025 Note Payable | (4,000) | — | ||
| Payment of Convertible Notes | (2,435) | — | ||
| Payment of insurance financing | (180) | — | ||
| Proceeds from Convertible Notes | — | 3,448 | ||
| Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $0 and $17 in 2026 and 2025, respectively | — | 1,756 | ||
| Repayment of insurance financing | — | (188) | ||
| Payment of Tempesta Note | — | (50) | ||
| Total cash provided by (used in) financing activities | (6,615) | 4,966 | ||
| Effects of foreign exchange rate changes on assets and liabilities | 17 | 36 | ||
| Net increase (decrease) in cash and restricted cash | 2,232 | (2,312) | ||
| Cash and restricted cash at beginning of the period | 7,832 | 8,002 | ||
| Cash and restricted cash at end of the period | $ | 10,064 | $ | 5,690 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| 2026 · 2025 | ||||
| Supplemental schedule of cash flow information | ||||
| Cash paid for interest | $ | 119 | $ | 6 |
| Supplemental schedule of non-cash financing and investing activities | ||||
| Stock dividends issued as Series O Convertible Preferred Stock | $ | 9,470 | $ | — |
| Warrants issued to Streeterville in exchange for Series L Preferred Stock | $ | 4,647 | $ | — |
| Deemed dividend to Streeterville related to conversion of Series L Preferred Stock | $ | 2,163 | $ | — |
| Warrants issued to Iliad in exchange for Series M Preferred Stock | $ | 1,910 | $ | — |
| Deemed dividend to Iliad related to conversion of Series M Preferred Stock | $ | 1,910 | $ | — |
| Warrants issued to Streeterville in exchange for Series M Preferred Stock | $ | 1,511 | $ | — |
| Deemed dividend to Streeterville related to conversion of Series M Preferred Stock | $ | 1,511 | $ | — |
| Warrants issued to Iliad in exchange for Series L Preferred Stock | $ | 479 | $ | — |
| Deemed dividend to Iliad related to conversion of Series L Preferred Stock | $ | 479 | $ | — |
| First Insurance Financing | $ | 62 | $ | 114 |
| Common shares issued to Irving in exchange of notes payable and accrued interest | $ | — | $ | 1,210 |
| Recognition of operating lease - right-of-use asset and operating lease liability | $ | — | $ | 341 |
| Common stock issued to Streeterville in exchange for notes payable and accrued interest | $ | — | $ | 315 |
| Cash and restricted cash | ||||
| Cash | $ | 7,278 | $ | 5,690 |
| Restricted cash | 2,786 | — | ||
| Total cash and restricted cash | $ | 10,064 | $ | 5,690 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.